Pre-clinical models of sepsis, have shown that blockade of the PD-1/PD-L1 pathway with an antagonistic anti-PD-L1 antibody improves survival by inhibiting lymphocyte apoptosis and T cell exhaustion (145, 149, 150). This evidence concerns the gene PDCD1 and Sepsis.